Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

RECOVERY (plasma), 2021
 
NCT04381936
RCTconvalescent plasma treatmentcontrolCOVID 19 hospitalizedNA
-/- inconclusive
    ACTIV-3/TICO LY-CoV555 , 2020
     
    NCT04501978
    RCTneutralizing antibodyplaceboCOVID 19 hospitalizedlow
    163/151 inconclusive
    • inconclusive 6 % increase in time to recovery (PE) with a high degree of certainty due to low risk of bias
    Balcells, 2020
     
    NCT04375098
    RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedlow
    28/30 inconclusive
    • inconclusive 33 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias
    ConPlas-19, 2020
     
    NCT04345523
    RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
    38/43 inconclusive
      Entrenas (Pilot Calcifediol), 2020
       
      NCT04366908
      RCTVitamin Dstandard of careCOVID 19 hospitalizedsome concern
      50/26 conclusif
      • inconclusive 88 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
      • demonstrated 97 % decrease in ICU admission (PE) with a moderate degree of certainty due to some concern in risk of bias
      Gharbharan et al., 2020
       
      NCT04342182
      RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
      43/43 inconclusive
      • inconclusive 5 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
      SOLIDARITY (interferon), 2020
       
      NCT04315948
      RCTinterferoncontrolCOVID 19 hospitalizedsome concern
      2063/2064 inconclusive
      • inconclusive 16 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
      Synairgen SG016, 2020
       
      NCT04385095
      RCTSNG001 inhaled interferon betaplaceboCOVID 19 hospitalizedhigh
      50/51 suggested
      • suggested 1.3-fold increase in clinical improvement but with a low degree of certainty due to high risk of bias
      Abolghasemi, 2020
       
      IRCT20200325046860N1
      OBSconvalescent plasma treatmentcontrolCOVID 19 hospitalizedcritical
      115/74 inconclusive
        Annweiler (GERIA-COVID; regular intake of bolus vitamin D), 2020 OBSVitamin DcontrolCOVID 19 hospitalizedNA
        29/32 suggested
        • suggested 93 % decrease in deaths (PE)
        • suggested 92 % decrease in death or ventilation
        Annweiler (GERIA-COVID; Vitamin D Supplementation After COVID-19 Diagnosis), 2020 OBSVitamin DcontrolCOVID 19 hospitalizedNA
        16/32 inconclusive

          COVID 19 all comers meta-analysis

          Cai -FAVIPIRAVIR, 2020
           
          ChiCTR2000029600
          NRainterferonlopinavir/ritonavirCOVID 19 all comersNA
          35/45 suggested
          • suggested 5.5-fold increase in clinical improvement,clinical improvement (14-day)
          Cai -FAVIPIRAVIR, 2020
           
          ChiCTR2000029600
          NRainterferoninterferonCOVID 19 all comersNA
          35/45 suggested
          • suggested 5.5-fold increase in clinical improvement,clinical improvement (14-day)

          COVID-19 mild to moderate meta-analysis

          Fu, 2020
           
          ChiCTR2000030262
          RCTinterferon / TFF2standard of careCOVID-19 mild to moderatesome concern
          40/40 no results
            Idelsis, 2020
             
            RPCEC00000307
            RCTinterferoninterferonCOVID-19 mild to moderatehigh
            30/33 conclusif
            • demonstrated 2.3-fold increase in PCR-negative conversion (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias
            Khamis, 2020 RCTinterferonstandard of careCOVID-19 mild to moderatesome concern
            44/45 inconclusive
              Libster, 2020
               
              NCT04479163
              RCTconvalescent plasma treatmentplaceboCOVID-19 mild to moderatelow
              80/80 conclusif
              • demonstrated 48 % decrease in clinical deterioration (PE) with a high degree of certainty due to low risk of bias
              PLACID, 2020
               
              CTRI/2020/04/024775
              RCTconvalescent plasma treatmentstandard of careCOVID-19 mild to moderatehigh
              235/229 suggested
              • inconclusive 7 % increase in death or transfer to ICU (PE) but with a low degree of certainty due to high risk of bias
              • suggested 20 % increase in PCR-negative conversion (7-day) but with a low degree of certainty due to high risk of bias
              Rastogi, 2020
               
              NCT04459247
              RCTVitamin DplaceboCOVID-19 mild to moderateNA
              16/24 suggested
              • suggested 5.3-fold increase in PCR-negative conversion (PE)
              Espitia-Hernandez, 2020 NRaVitamin Dstandard of careCOVID 19 outpatients, COVID-19 mild to moderateNA
              28/7 suggested
              • suggested 714.0-fold increase in PCR-negative conversion

              COVID-19 severe or critically meta-analysis

              AlQahtani, 2020
               
              NCT04356534
              RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
              20/20 inconclusive
              • inconclusive 33 % decrease in ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
              Bajpai M, 2020
               
              NCT04346446
              RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallyhigh
              14/15 inconclusive
              • inconclusive 74 % decrease in off oxygenation (PE) but with a low degree of certainty due to high risk of bias
              Davoudi-Monfared, 2020
               
              IRCT20100228003449N2
              RCTinterferonstandard of careCOVID-19 severe or criticallyhigh
              46/46 no results
                Murai, 2020
                 
                NCT04449718
                RCTVitamin DplaceboCOVID-19 severe or criticallysome concern
                120/120 inconclusive
                  PlasmAr, 2020
                   
                  NCT04344535
                  RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallylow
                  228/105 inconclusive
                  • inconclusive 19 % decrease in clinical improvement (PE) with a high degree of certainty due to low risk of bias
                  PlasmAr, 2020
                   
                  NCT04344535
                  RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
                  228/105 inconclusive
                  • inconclusive 19 % decrease in clinical improvement (PE) with a high degree of certainty due to low risk of bias
                  Yekaninejad, 2020
                   
                  IRCT20100228003449N2
                  RCTinterferonstandard of careCOVID-19 severe or criticallysome concern
                  33/33 conclusif
                  • demonstrated 2.4-fold increase in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                  Li, 2015
                   
                  ChiCTR2000029757
                  RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
                  52/51 inconclusive
                  • inconclusive 40 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
                  Duan, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
                  10/10 inconclusive
                    Hegerova, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
                    20/20 inconclusive
                      Rasheed, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
                      21/28 inconclusive
                        Sean, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
                        39/156 inconclusive
                          Joyner, 2020
                           
                          NCT04338360
                          NRaconvalescent plasma treatmentconvalescent plasma treatmentCOVID-19 severe or criticallyserious
                          515/561 inconclusive

                            PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                            Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).